A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours.
Kang YJ, O'Haire S, Franchini F, IJzerman M, Zalcberg J, Macrae F, Canfell K, Steinberg J.
Kang YJ, et al.
Sci Rep. 2022 Nov 28;12(1):20495. doi: 10.1038/s41598-022-23319-1.
Sci Rep. 2022.
PMID: 36443366
Free PMC article.
The prevalence profiles of dMMR/MSI and high TMB differed across cancer types. For example, endometrial, colorectal, small bowel and gastric cancers showed high prevalence of both dMMR and MSI (range: 8.7-26.8% and 8.5-21.9%, respectively) and high TMB …
The prevalence profiles of dMMR/MSI and high TMB differed across cancer types. For example, endometrial, colorectal, small bowel and …